Cell Line Development and Characterization: An Ocean of Opportunities for Service Providers

The growing pipeline of monoclonal antibodies, vaccines, enzymes, biosimilars and other therapeutic proteins have actually produced an ever- increasing demand for extremely- efficient and steady cell lines. Offered their impact on the general quality of therapeutic protein, it is important to bring out cell line characterization, at various phases of biopharmaceutical production, to guarantee the purity and origin of the manufacturer cell line. The requirement of expense extensive product, complicated advancement and purification procedures, pricey characterization and documents treatments, the need for specialized technologies/ facilities for the production and storage of cell lines and emergence of advanced analytical strategies, have actually led to an increase in outsourcing in this domain.

Given the effort to halt the COVID-19 pandemic, we are led to think that one of the contributing aspects towards the development of cell line development and characterization services market is the competence offered with the provider to establish genetically engineered cell lines, which might function as prospective protein producing factories, for big scale commercialization of the vaccine against the SARS-CoV-2.

Players Offering Cell Line Development and Characterization Services

Currently, over 220 business/ organizations across the world claim to provide services for cell line development from a variety of sources, to support cell-based R&D operations and assist in bio-therapeutics production. As per our research, close to 80% of these gamers in addition offer analytical and purification services for proteins, in order to guarantee the quality and pureness of biologics produced from cell lines. Examples of gamers, which have actually established complete suite of services and serve as one stop buy drug designers, consist of (in alphabetical order) Lonza, Samsung Biologics and WuXi Biologics.

In addition to this, we determined over 80 business that provide cell line characterization services; around 76% of these define mammalian cell lines, followed by companies that identify microbial cells (41%). Examples of gamers characterizing mammalian, microbial and insect cells, include (in alphabetical order) Accelero Bioanalytics, Eurofins Genomics, LivoGen Pharmed and SGS Life Sciences. Several non- industry gamers have also taken considerable efforts in this domain.

Which Type of Deals are being Inked in this Domain?

Majority of the partnerships (23%), inked by the stakeholders in this domain, were focused on licensing of cell lines/ designs, biologics and/ or technology platforms associated with cell lines. Examples of the just recently signed licensing deals include (in reverse sequential order) collaboration in between Horizon Discovery and TrueBinding (July 2020), Horizon Discovery and Rentschler Biopharma (May 2020) and CEVEC Pharmaceuticals and Evox Therapeutics (April 2020). In the second and 3rd quarter of 2020, the company participated in a variety of arrangements related to the development of vaccine against SARS-CoV-2, representing the energy of cell lines for the treatment of contagious diseases; examples of offers inked for the development of vaccine against COVID-19 include (in reverse sequential order) partnership between Northway Biotechpharma and Memo Therapeutics (August 2020), Catalent Pharma Solutions and Spicona (June 2020), Aragen Bioscience and Oragenics (May 2020).

Likely Growth of the Cell Line Development and Characterization Services Market

Further, the cell line characterization services market is expected to witness a CAGR of nearly 13%. Currently, majority of earnings is produced from jobs connected to the characterization of mammalian cell lines (88%). The pattern is not likely to alter in the visualized future.

Throughout our research study, we estimated the market under conservative, base and positive scenarios. According to the base case forecast situation, rye market for cell line advancement services is estimated to be worth over USD 5.3 billion, growing at an annualized rate of 13.7%, in the provided period. The opportunity is most likely to be well distributed across different locations, cell lines sources, applications and company sizes.

Cell Line Development and Characterization: Whats New?

Provided their effect on the total quality of therapeutic protein, it is crucial to bring out cell line characterization, at different phases of biopharmaceutical production, to make sure the pureness and origin of the manufacturer cell line. The requirement of expense intensive product, complicated development and filtration processes, expensive characterization and documentation treatments, the need for specialized innovations/ infrastructure for the production and storage of cell lines and emergence of sophisticated analytical techniques, have actually led to a boost in outsourcing in this domain. We identified over 80 companies that use cell line characterization services; around 76% of these characterize mammalian cell lines, followed by business that characterize microbial cells (41%). Bulk of the collaborations (23%), inked by the stakeholders in this domain, were focused on licensing of cell lines/ models, biologics and/ or technology platforms related to cell lines. In the 3rd and 2nd quarter of 2020, the service providers got in into a number of arrangements related to the development of vaccine versus SARS-CoV-2, representing the energy of cell lines for the treatment of transmittable diseases; examples of deals inked for the advancement of vaccine against COVID-19 include (in reverse sequential order) partnership between Northway Biotechpharma and Memo Therapeutics (August 2020), Catalent Pharma Solutions and Spicona (June 2020), Aragen Bioscience and Oragenics (May 2020).

Cell Line Development and Characterization Services.

HUMIRA ® (Adalimumab) Biosimilars: Focus on Approved & & Launched Biosimilars, Investigational & & Research Use Biosimilars, Inactive/ Terminated/ Withdrawn Biosimilars, Industry/ Non-Industry Partnerships.
CRISPR Based Therapeutics Market, 2021-2030.

Having said that, our company believe that in pursuit of checking out “an ocean of chances”, these service suppliers will continue to add to the technological evolution in this domain, in the visualized future!

In the current years, the evolution of CRISPR and other gene editing technologies, has led to the advancement of customized knockout, knock-in and protein over-expressing cell lines. Further, lots of players have established their own cell- based unique and innovative technologies, to lower production expenses and production timelines.

For comprehensive insights about this domain, inspect out our report.

You may also be interested in the following titles:.

Display Library Technologies and Affiliated Services Market, 2021-2030.

Leave a Reply

Your email address will not be published. Required fields are marked *